Anna Myers
Nurse Practitioner · Richfield, OHNPI 1821430620
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 74.3% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $12,828 and has fallen 74.8% since, to $3,235 in 2025. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $101.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$15K
- Axonics, Inc.$2K
- Sumitomo Pharma America, Inc.$661
- Convatec Inc.$519
- AbbVie$408
- Bluewind Medical$186
- plus $1K from 22 others
What the payments were for
- Consulting fees$1,99510%
- Speaking & faculty fees$10,23550%
- Travel & lodging$2,52812%
- Food & beverage$5,06124%
- Education$8404%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 57 | $15,344 |
| Axonics, Inc. | 47 | $2,439 |
| Sumitomo Pharma America, Inc. | 23 | $661 |
| Convatec Inc. | 7 | $519 |
| AbbVie(2 entities) | 21 | $408 |
| Bluewind Medical | 3 | $186 |
| Teleflex LLC | 3 | $181 |
| Johnson & Johnson | 6 | $166 |
| Antares Pharma, Inc. | 5 | $89 |
| Scynexis, Inc. | 1 | $75 |
| Coloplast | 5 | $68 |
| 180 Medical, Inc. | 2 | $52 |
| Rochester Medical Corporation | 1 | $46 |
| Urovant Sciences Inc | 3 | $45 |
| Boston Scientific | 3 | $43 |
| Olympus America Inc. | 2 | $40 |
| Urogen Pharma, Inc. | 2 | $40 |
| Immunitybio, Inc. | 1 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Bayer | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| BD | 1 | $25 |
| Medtronic | 1 | $24 |
| Endo USA, Inc. | 1 | $23 |
| Tempus AI, Inc | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| Davol Inc. | 1 | $20 |
| Photocure Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,658 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 441 | $359,897 |
| MyrbetriqMirabegron | 343 | $256,950 |
| Estradiol | 405 | $29,314 |
| Mirabegron ErMirabegron | 37 | $21,184 |
| Trospium Chloride ErTrospium Chloride | 39 | $7,220 |
| Trospium Chloride | 87 | $7,038 |
| Solifenacin Succinate | 125 | $5,848 |
| Tamsulosin Hcl | 259 | $5,089 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 195 | $2,389 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 24 | $2,106 |
| Cephalexin | 176 | $1,937 |
| Trimethoprim | 19 | $1,844 |
| Clobetasol Propionate | 63 | $1,618 |
| Gentamicin Sulfate | 58 | $1,244 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 69 | $1,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $661 | $359,897441 claims |
| Astellas Pharma US IncMyrbetriq | $15,344 | $256,950343 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Richfield
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.